For all their remarkable effectiveness, the current GLP-1 drugs have some limitations
Watch for more details coming about important points in this program
Sattar N, Lee MMY, Kristensen SL, et al
This is mainly because of the reported weight loss While GLP-1 medications Zepbound and This rapid increase in users of GLP-1 drugs has caused Now, a new study published in Annals of Internal Medicine , reports that among the approximately 1 million new GLP-1 medication users identified between 2011 to 2023, there was a twofold increase in GLP-1 medication users who do not have type 2 diabetes but do have a body mass index (BMI) of 30 killograms per square meter (kg/m 2 ) or greater, and in people with a BMI of 27 to 30 kg/m 2 and an obesity-related The researchers also found that the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023
While this potential blockbuster treatment presents considerable opportunities for pharma partners, there are, of course, challenges, specifically in terms of satisfying demand
Customized for advanced metabolic optimization
